Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ : Health Technology
Prev Close 284.18
Day Low/High 279.47 / 287.00
52 Wk Low/High 271.57 / 442.00
Avg Volume 757.00K
Exchange NASDAQ
Shares Outstanding 107.98M
Market Cap 31.23B
EPS 22.60
P/E Ratio 15.49
Div & Yield N.A. (N.A)

A Nutty Environment

Sometimes the facts just don't fit the story.

Names in the News

Tesla, GM, Annie's, Regeneron, and Sprint are all making headlines. By Bret Jensen Tesla Motors (TSLA) has been in the news recently for its move into China. CEO Elon Musk (never the shy one) states that sales in the Middle Kingdom could equal those...

Time to Consider Some Shorts

Time to Consider Some Shorts

Here are some candidates on my watch list.

A Gift-Wrapped Buy Entry

Regeron's technicals -- and the current pullback -- all add up to a buy.

These Stocks Deserve Faith

Believe in CEOs with a history of winning seasons.

Where to Buy in 2014: Part II

Here are four more themes where you can put money to work.

Off the Charts

Off the Charts

Cliffs Natural Resources is on our watch-list after forming a rounding bottom.

Time to Reconsider Sector Weights

Rather than follow the crowd, I want to lead it.

Off the Charts

Off the Charts

We add Baidu to our long watch-list today as it holds higher at upper levels.

Is There Still a Play to Be Made on Regeneron?

An inverse head and shoulders pattern could soon develop.

Big Pharma Emerges From the Wilderness

These four names are soaring, and I'd jump into all of them, even after their recent runs.

Washington Driving These Stock Ideas

Auto-loan regulation could rattle some publicly traded auto dealers.

Stock Bargains Left on the Table

Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.

Cramer: The Top-Calling Finally Arrives

Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.

Rate Scares Are Ruling the Market

Treasuries are calling the tune today, regardless of companies' fundamentals.

ECB Won't Cut Interest Rates

ECB Won't Cut Interest Rates

Though data suggest a softer eurozone recovery than expected, EverBank's Frank Trotter says it's unlikely the ECB will cut rates.

Easy Choices in the Pharma Patch

Merck is shunned by all; Biogen is liked by all; and Bristol-Myers is the holy grail.

Cramer: It's a Shame About Washington

We're getting positive news from businesses all over the place -- yet none of it will matter if the U.S. defaults.

Understanding the Highflying Stocks

When forces line up against them, they tend to fall hard.

Cramer's 2,000th Mad Money Episode

Cramer's 2,000th Mad Money Episode

Jim Cramer reflects on 2,000 episodes for Mad Money and the importance of individual stock picking.

Do Not Read This, Herb

It's best for Mr. Greenberg to avert his eyes.

Apple Loses the Playbook

The company has forgotten how to under-promise and over-deliver.

Pounce on the Anointed Ones

These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.

No Rhyme or Reason

This market doesn't know what it wants, so it's a good time to stand aside.

COG, NFLX, REGN: 3 Stocks on TV

COG, NFLX, REGN: 3 Stocks on TV

Dan Fitzpatrick, founder of, details three stocks Jim Cramer discussed on CNBC's "Mad Money" and how to trade them.

Regeneron estimated raised at UBS

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...